Atypical antipsychotics for psychosis in adolescents

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 10, 2013, Pages

  Kumar, Ajit ^a   Datta, Soumitra S ^b,c   Wright, Stephen D ^a   Furtado, Vivek A ^d   Russell, Paul S ^e  

^a LEEDS AND YORK PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c Department of Palliative Care and Psycho oncology ^*  (India)

^d UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^e CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; LURASIDONE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; BENZODIAZEPINE DERIVATIVE; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADOLESCENT; ANTICHOLINERGIC SYNDROME; BODY WEIGHT DISORDER; DROWSINESS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; PARKINSONISM; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PSYCHOSIS; PSYCHOSOCIAL CARE; RESTLESSNESS; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SYSTEMATIC REVIEW; TREMOR; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); PSYCHOTIC DISORDERS;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; HUMANS; MOLINDONE; PIPERAZINES; PSYCHOTIC DISORDERS; QUINOLONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISPERIDONE; SCHIZOPHRENIA;

EID: 84895762389     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009582.pub2     Document Type: Review

References (174)

1. Aranda OR, Zabala A, Bombn I, Burdalo M, Sancho AR, Moreno D, et al.Quetiapine and olanzapine cognitive efficacy in adolescents with early onset psychosis. Schizophrenia Bulletin 2007;33(2):456.
2. Parellada MJ, Moreno D, Ruiz-Sancho A, Medina O, Arango C. Open-label randomized trial comparing the efficacy and tolerability of quetiapine and olanzapine in first episode psychosis in adolescents. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S377.
3. Robles O, Zabala A, Parellada MJ, Ruiz A, Moreno MD, Burdalo MT, et al.Cognitive efficacy of quetiapine and olanzapine in early onset first episode psychosis. Journal of the European College of Neuropsychopharmacology 2006;16(Suppl 4):S381.
4. DelBello MP, Versavel M, Ice K, Keller D, Miceli J. Tolerability of oral ziprasidone in children and adolescents with bipolar mania, schizophrenia, or schizoaffective disorder. Journal of Child and Adolescent Psychopharmacology 2008;18(5):491-9. [PUBMED: 18928413]
5. DelBello MP, Versavel M, Ice K, Keller D, Miceli J. Ziprasidone dosing study in pediatric patients with bipolar disorder, schizophrenia or schizoaffective disorder. 13th Biennial Winter Workshop on Schizophrenia Research, 2006 February 4-10, Davos, Switzerland.
6. Carson WH, Nyilas M, Forbes RA, Pikalov A, McQuade RD, Owen R, et al.A 6-week study of the efficacy and tolerability of aripiprazole in pediatric patients with schizophrenia. Schizophrenia Research 2008;98:41-2.
7. Carson WH, Nyilas M, Forbes RA, Pikatov A, McQuade RD, Owen R, et al.A 6-week study of the efficacy and tolerability of aripiprazole in pediatric patients with schizophrenia. 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders, 2008 February 3-7, Montreux, Switzerland.
8. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al.A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. The American Journal of Psychiatry 2008;165(11):1432-41. [PUBMED: 18765484]
9. Nyilas M, Findling RL, Johnson B, Forbes RA, Pikalov A, Marcus R, et al.Efficacy and tolerability of aripiprazole in adolescents with schizophrenia. 46th Annual Meeting of the American College of Neuropsychopharmacology, 2007 December 9-13, Boca Raton, Florida, USA.
10. Otsuka Pharmaceutical Development & Commercialization Inc. Aripiprazole in adolescents with schizophrenia, 2005. http:www.clinicaltrials.gov.
11. Haas M, Eerdekens M, Kushner S, Singer J, Augustyns I, Quiroz J, et al.Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. The British Journal of Psychiatry 2009;194(2):158-64. [PUBMED: 19182179]
12. Huo W-H, Ma Y-B, Li G-Z. A controlled study of risperidone in child schizophrenia Medical Journal of Chinese People's Health 2007;19(11):472-3. [CHINESE: Academic Journals; MEDLINE: ]
13. Jensen J, Sculz SC. A comparative study of new medications for psychosis in adolescents, 2005. http:www.clinicaltrials.gov.
14. Jensen JB, Kumra S, Leitten W, Oberstar J, Anjum A, White T, et al.A comparative pilot study of second-generation antipsychotics in children and adolescents with schizophrenia-spectrum disorders. Journal of Child and Adolescent Psychopharmacology 2008;18(4):317-26. [PUBMED: 18759641]
15. Jensen JB, Leitten W, Wozniak J, Anjum A, White T, Oberstar J, et al.Efficacy and tolerability of atypical antipsychotics in adolescents with psychosis. Schizophrenia Bulletin 2007;33(2):434.
16. Dittmann RW, Krzyhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Robertson-Plouch C, et al.Results from a double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. Schizophrenia Research 2006;86(Suppl 1):S133.
17. Eli Lilly, Company. Olanzapine versus placebo in the treatment of adolescents with schizophrenia. Eli Lilly and Company Clinical Trial Registry, 2002.
18. Eli Lilly, Company. Olanzapine versus placebo in the treatment of adolescents with schizophrenia, 2003. http:www.clinicaltrials.gov.
19. Joan S, Earley WR, Kryzhanovskaya L, Miner C, Dittmann RW. Olanzapine in the treatment of schizophrenia in adolescents: an ongoing double-blind placebo-controlled study. Schizophrenia Bulletin 2005;31:489.
20. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Dittmann RW, Robertson-Plouch C, et al.A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. 13th Biennial Winter Workshop on Schizophrenia Research, 2006 February 4-10, Davos, Switzerland.
21. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Dittmann RW, Robertson-Plouch C, et al.Results from a double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. 5th International Conference on Early Psychosis, 2006 October 4-6, Birmingham, United Kingdom.
22. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Dittmann RW, Tohen MF. A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. 159th Annual Meeting of the American Psychiatric Association, 2006 May 20-25, Toronto, Canada.
23. Kryzhanovskaya L, Schulz C, McDougle CJ, Frazier JA, Shen J, Dittman R, et al.A double-blind, placebo-controlled study of olanzapine in adolescents with schizophrenia. Neuropsychopharmacology 2005;30(Suppl 1):S258-9.
24. Kryzhanovskaya L, Schulz SC, McDougle C, Frazier J, Dittmann R, Robertson-Plouch C, et al.Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry 2009;48(1):60-70. [PUBMED: 19057413]
25. Frazier JA, Gordon CT, McKenna K, Lenane MC, Jih D, Rapoport JL. An open trial of clozapine in 11 adolescents with childhood onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry 1994, issue 5:658-63. [MEDLINE: 94334254; PMID: 8056728]
26. Gordon CT, Frazier JA, McKenna K, Giedd J, Zametkin A, Zahn T, et al.Childhood-onset schizophrenia: an NIMH study in progress. Schizophrenia Bulletin 1994, issue 4:697-712. [MEDLINE: 95215796; PMID: 7701277]
27. Kumra S, Frazier JA, Jacobsen LK, McKenna K, Gordon CT, Lenane MC, et al.Childhood-onset schizophrenia: a double-blind clozapine-haloperidol comparison. Archives of General Psychiatry 1996;53(12):1090-7. [MEDLINE: 97115273;: PMID 8956674]
28. Kumra S, Jacobsen LK, Rapoport JL. Childhood-onset schizophrenia - a double-blind clozapine trial. 149th Annual Meeting of the American Psychiatric Association, 1996 May 4-9, New York, NY, USA. [MEDLINE: 97115273; PMID: 8956674]
29. Piscitelli SC, Frazier JA, McKenna K, Albus KE, Grothe DR, Gordon CT, et al.Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. Journal of Clinical Psychiatry 1994, issue Suppl B:94-7. [MEDLINE: 95050401; PMID: 7961584]
30. Kumra S, Kranzler H, Gerbino-Rosen G, Kester HM, DeThomas C, Kafantaris V, et al.Clozapine and "high-dose" olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biological Psychiatry 2008;63(5):524-9. [EMBASE: 2008071168; MEDLINE: 0; MEDLINE: 17651705;: PsycINFO]
31. Kumra S, Kranzler H, Moise F, McCarthy J, Kafantaris V, Kane JM. Treating refractory childhood schizophrenia, 2002. http:www.clinicaltrials.gov.
32. Sikich L, Hamer RM, Bashford RA, Sheitman BB, Lieberman JA. A pilot study of risperidone, olanzapine, and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology 2004;29(1):133-45. [: EMBASE: 2004025276; 14583740 PMID]
33. Sikich L, Hooper SR, Malekpour AH, Sheitman BB, Lieberman JA. A double blind comparison of typical versus atypical antipsychotic agents on selected neurocognitive functions in children and adolescents with psychotic disorders. Schizophrenia Research 2001, issue 1, 2:245. [MEDLINE: 21416786; PMID: 11525078]
34. Sikich L, Horrigan JP, Lieberman JA, Barnhill LJ Jr, Sheitman BB, Courvoisie HE. Comparative use of olanzapine and risperidone in psychotic youth. 155th Annual Meeting of the American Psychiatric Association, 2002 May 18-23, Philadelphia, PA, USA.
35. Sikich L, Horrigan JP, Lieberman JA, Barnhill LJ, Sheitman BB, Courvoisie HE. Comparative use of olanzapine and risperidone in psychotic youth. 154th Annual Meeting of the American Psychiatric Association, 2001 May 5-10, New Orleans, LA, USA. [MEDLINE: 21185887; PMID: 11290639]
36. Sikich L, Williamson K, Malekpour A, Bashford RA, Hooper S, Sheitman B, et al.Interim results of a randomized controlled trial of haloperidol, risperidone, and olanzapine in psychotic youth. 38th Annual Meeting of the American College of Neuropsychopharmacology, 1999 December 12-16, Acapulco, Mexico.
37. Sikich L. Treatment of schizophrenia and related disorders in children and adolescents, 2003. http:www.clinicaltrials.gov.
38. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al.Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. The American Journal of Psychiatry 2008;165(11):1420-31. [PUBMED: 18794207]
39. Swadi HS, Craig BJ, Pirwani NZ, Black VC, Buchan JC, Bobier CM. A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. International Clinical Psychopharmacology 2010;25(1):1-6. [PUBMED: 19809337]
40. Xiong Y. Comparison study of childhood schizophrenia treated with risperidone and chlorpromazine. Guizhou Medical Journal 2004;28(8):697-8. [MEDLINE: 939850;: ]
41. Amminger GP, Schafer MR. Indicated prevention with omega-3 fatty acids in adolescents at ultra-high risk for psychosis - rationale, methods, and 3-months outcome. Schizophrenia Research 2006;86(Suppl 1):S97-8.
42. Amminger GP, Schafer MR. Is it feasible to conduct a RCT in ultra-high risk individuals at a child and adolescent psychiatric service?. Schizophrenia Research 2006;86(Suppl 1):S98.
43. Antropov IUF. Various methods of overcoming resistance to therapy in childhood and adolescent schizophrenia [O nekotorykh metodakh preodoleniia terapevticheskoi rezistentnosti pri shizofrenii u detei i podrostkov]. Zhurnal Nevropatologii i Psikhiatrii imeni S.S. Korsakova 1981, issue 10:1522-6. [MEDLINE: 82087113; PMID: 6118983]
44. Berger G. A naturalistic, prospective, single centre, double blinded, fixed dose, randomised, four week comparison study investigating efficacy, tolerability and safety of 200 mg per day versus 400 mg per day quetiapine fumarate in 200 drug naïve first episode psychosis patients aged 15 to 25 years, 2007. http:www.clinicaltrials.gov.
45. Bertelsen M. Randomized controlled trial of two years integrated treatment versus standard treatment of patients with first episode of schizophrenia or psychosis, five years follow-up. The OPUS trial. Schizophrenia Bulletin 2005;31:519-20.
46. Buchsbaum MS, Haznedar MM, Aronowitz J, Brickman AM, Newmark RE, Bloom R, et al.FDG-PET in never-previously medicated psychotic adolescents treated with olanzapine or haloperidol. Schizophrenia Research 2007;94(1-3):293-305. [MEDLINE: 0; MEDLINE: 17574821;: PsycINFO]
47. Buchsbaum MS, Haznedar MM, Hazlett E. Antipsychotic response prediction with FDG-PET in schizophrenia. Thematic Conference of the World Psychiatric Association on "Treatments in psychiatry: an update, " 2004 November 10-13, Florence, Italy.
48. Chen P. [Title available only in Chinese characters] Linchuang Jingshen Yixue Zazhi 2007;17(1):54. [CHINESE: Academic Journals; MEDLINE: ]
49. Davidson M. Reducing the risk of early transition to psychosis: using long-acting atypical antipsychotics in young patients. Thematic Conference of the World Psychiatric Association on "Treatments in psychiatry: an update, " 2004 November 10-13, Florence, Italy.
50. Gao C. A comparative study of risperidone and perphenazine in the treatment of child schizophrenia Chinese Journal of Health Psychology 2007;15(10):950-1. [CHINESE: Academic Journals; MEDLINE: ]
51. Jenner J, Van De Willige G. Results of integrated treatment (HIT) in early psychoses: a pilot study. Schizophrenia Research 2004;70(1):16.
52. Johnson & Johnson Pharmaceutical Research & Development LLC. A randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of risperidone for the treatment of schizophrenia in adolescents, 2004. http:www.clinicaltrials.gov.
53. Killackey E, Jackson H, McGorry P. Vocational intervention in a specialist early psychosis service: first results of a pilot randomised controlled trial. Schizophrenia Research 2006;86(Suppl 1):S28-9.
54. Klier C, Hollmann M, Schlögelhofer M, Mossaheb N, Friedrich M, Amminger PG. Indicated prevention with omega-3 fatty acids (EPA/DHA) in adolescents with "at-risk-mental-state" for psychosis. XIII World Congress of Psychiatry, 10-15 September 2005, Cairo, Egypt.
55. Leblanc J, Letourneau K, Demers MF, Bouchard RH, Roy MA. The impact of modafinil as an adjunct to a second generation antipsychotic on cognitive functioning in patients with first psychotic episode. Schizophrenia Research 2006;86(Suppl 1):S131.
56. Leclerc C, Gauvin D, Lecomte T. CBT group to maintain and improve relationships and intimacy abilities of young adults with a first psychotic episode - a pilot study. Schizophrenia Research 2006;86(Suppl 1):S138-9.
57. Liang Ligui. A clinical trial of risperidone in treatment of childhood patients with first-episode schizophrenia. Journal of Clinical Psychological Medicine 2003, issue 01.
58. Linszen D, De Haan L, Dingemans P, Lenior R, Van Amelsvoort T, Wouters L. The Amsterdam critical period intervention in the early phase of schizophrenia-like psychoses. Schizophrenia Research 2006;86(Suppl 1):S61.
59. Lv L-X, Guo S-Q, Chen W, Li Q, Cheng J, Zhang H-Y, et al.Effects of clozapine and risperidone on serum interleukin-2, -10, -18 in adolescent schizophrenia patients. Journal of Applied Clinical Pediatrics 2004;19(11):983-6. [EMBASE: 2004428997; MEDLINE: ]
60. Malik SC, Kumar K. Loxapine in adolescent schizophrenia - a comparative study with trifluoperazine. Current Therapeutic Research Clinical and Experimental 1980;28(3):432-46. [MEDLINE: 88249199;: PMID 3381314]
61. Mathai J, Bourne A. Pilot study investigating the effect of intercessory prayer in the treatment of child psychiatric disorders. Australasian Psychiatry 2004;12(4):386-9.
62. McConville B, Carrero L, Sweitzer D, Pott Larry, Chaney R, Foster K, et al.Long-term safety, tolerability, and clinical efficacy of quetiapine in adolescents: an open-label extension trial. Journal of Child & Adolescent Psychopharmacology 2003, issue 1:75-82.
63. Hawkins KA, Addington J, Keefe RS, Christensen B, Woods SW, Zipursky RB, et al.Effect of olanzapine vs. placebo on the neuropsychological status of prodromal subjects. 12th Biennial Winter Workshop on Schizophrenia, 2004 February 7-13, Davos, Switzerland.
64. Hoffman RE, Woods SW, Hawkins KA, Pittman B, Tohen M, Preda A, et al.Extracting spurious messages from noise and risk of schizophrenia-spectrum disorders in prodromal population. British Journal of Psychiatry 2007;191(2):355-6.
65. McGlashan TH, Miller TJ, Zipursky RB, Woods SW, Perkins DO, Hawkins KA, et al.Intervention in the schizophrenic prodrome: the prevention through risk identification, management, and education initiative. 156th Annual Meeting of the American Psychiatric Association, 2003 May 17-22, San Francisco, CA, USA.
66. McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, et al.The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophrenia Research 2003;61(1):7-18. [MEDLINE: 12648731; MEDLINE: 22536522]
67. McGlashan TH, Zipursky RB, Perkins DO, Addington J, Woods SW, Miller TJ, et al.Olanzapine versus placebo treatment of the schizophrenia prodrome: one year results. Schizophrenia Research 2003;60:295.
68. Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KAHR, et al.The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample. Schizophrenia Research 2003;61(1):19-30. [MEDLINE: 12648732; MEDLINE: 22536523]
69. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al.Olanzapine versus placebo for prodromal symptoms. Schizophrenia Research 2003;60:306-7.
70. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al.Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biological Psychiatry 2003;54(4):453-64. [MEDLINE: 12915290;: ]
71. Woods SW, Breier A, Zipursky RB, Perkins DO, Addington J, Miller TJ, et al.Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. [erratum appears in Biological Psychiatry 2003 Aug 15;54(4):497]. Biological Psychiatry 2003, issue 4:453-64.
72. McGorry PD, Phillips LJ, Nelson B, Leicester S, Baker K, Krstev H, et al.A double blind, placebo-controlled randomized trial of low-dose risperidone, cognitive-behaviour therapy, and befriending in young people with subthreshold symptoms at incipient risk of psychotic disorder: six month outcome data. Schizophrenia Bulletin 2007;33(2):446.
73. Nelson B, Phillips LJ, Yung AR, Francey SM, Leicester S, Baker K, et al.A double blind, placebo-controlled randomized trial of low-dose risperidone, intensive psychological treatment and supportive therapy in young people with subthreshold symptoms at incipient risk of psychotic disorder: baseline characteristics of the sample. Schizophrenia Bulletin 2007;33(2):450.
74. Newton E, Landau S, Smith P, Monks P, Shergill S, Wykes T. Early psychological intervention for auditory hallucinations: an exploratory study of young people's voices groups. Journal of Nervous and Mental Disease 2005;193(1):58-61. [MEDLINE: 2005088980 NLM Unique Identifier: 15674136;: ]
75. Otsuka Pharmaceutical Development & Commercialization Inc. A phase II study to test PK tolerability in children and adolescents, 2005. http:www.clinicaltrials.gov.
76. Power P, Craig T, Garety P, Rahaman N, Colbert S, Fornells-Ambrojo M. Lambeth early onset (LEO) trial: a randomised controlled trial of assertive community follow-up in early psychosis: initial 6 month data. Unknown source 1994. [MEDLINE: 9111852;: ]
77. Power P, Craig T, Mcguire P, Iacoponi E, Garety P, Russell M. A randomised controlled trial of an early detection team in first episode psychosis: the LEO cat trial. Schizophrenia Research 2004;67(1):36. [ISI: 000188788100082; MEDLINE: ]
78. Schepp KG. Self-management therapy for youth with schizophrenia, 1999. http:www.clinicaltrials.gov.
79. Sela B-A, Stahl Z, Gavendo S, Ruderman V, Belmaker RH, Levine J. Homocysteine reducing strategy in young male schizophrenic patients: effects on symptoms and cognition. Journal of Inherited Metabolic Disease 2003;26(Suppl 1):102.
80. Stain HJ, Startup M, Carr V, Baker A, Schall U. The depth project: a multisite RCT for youths at risk for psychosis. Schizophrenia Research 2006;86(Suppl 1):S51-2.
81. Tandon R, Sitholey P, Katiyar M, Kumar A. Short term tolerability of risperidone in children and adolescents with acute and transient psychotic disorders. XIII World Congress of Psychiatry, 10-15 September 2005, Cairo, Egypt.
82. Ueland T, Rund BR. A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis. Acta Psychiatrica Scandinavica 2004, issue 1:70-4.
83. Ueland T, Rund BR. Cognitive remediation for adolescents with early onset psychosis: a 1-year follow-up study. Acta Psychiatrica Scandinavica 2005;111(3):193-201. [PUBMED: 15701103]
84. van Bruggen J, Tijssen J, Dingemans P, Gersons B, Linszen D. Symptom response and side-effects of olanzapine and risperidone in young adults with recent onset schizophrenia. International Clinical Psychopharmacology 2003;18(6):341-6.
85. van Nimwegen L, de Haan L. Early withdrawal in a double-blind randomized clinical trial with olanzapine and risperidone performed in adolescents with first psychosis. Psychopathology 2006;39(3):158. [EMBASE: 160407; MEDLINE: 16531692]
86. van Nimwegen L, de Haan L, van Beveren N, Laan W, van de Brink W, Linszen D. Obsessive compulsive symptoms in a randomized double blind study with olanzapine or risperidone in young patients with recent-onset schizophrenia or related disorders. 13th Biennial Winter Workshop on Schizophrenia, 6-10 February 2006, Davos, Switzerland.
87. van Nimwegen L, de Haan L, van Beveren N, Laan W, van den Brink W, Linszen D. Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. Journal of Clinical Psychopharmacology 2008;28(2):214-8. [EMBASE: 2008140943; MEDLINE: 0; MEDLINE: 18344733;: PsycINFO]
88. Versiani Marcis, da Silva JA, Frota LH, Mundim FD. Double-blind comparison between loxapine and haloperidol in the treatment of adolescent schizophrenic patients. Current Therapeutic Research 1978;24:559-66. [: PsycINFO 63-03832]
89. Wang H. [Title available only in Chinese characters] Linchuang Jingshen Yixue Zazhi 2007;17(3):199-200. [CHINESE: Academic Journals; MEDLINE: ]
90. Newton E, Landau S. Cognitive remediation therapy (CRT): a new psychological treatment for young patients with schizophrenia. Schizophrenia Research 2006;86(Suppl 1):S143-4.
91. Wykes T. Cognitive remediation for young people with schizophrenia. Current Controlled Trials 2006. [ISRCTN: 75187865; MEDLINE: ]
92. Wykes T. Cognitive remediation therapy (CRT)) for young people with schizophrenia. 2nd International Conference on Early Psychosis, 2000 Mar 31-Apr 2, New York, NY, USA. [EMBASE:: 2004180181; MEDLINE: ]
93. Wykes T, Newton E, Landau S, Rice C, Thompson N, Frangou S. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophrenia Research 2007;94(1-3):221-30. [PUBMED: 17524620]
94. Wykes T, Newton E, Landau S, Rice C, Thompson N, Frangou S. Remediation in adolescent onset results of a randomised control trial. Schizophrenia Bulletin 2007;33(2):610.
95. Wykes T, Reeder C, Williams C, Corner J, Rice C, Everitt B. Are the effects of cognitive remediation therapy (CRT) durable? Results from an exploratory trial in schizophrenia. Schizophrenia Research 2003;61(2-3):163-74. [MEDLINE: 12729868;: CN-00456712.]
96. Xiu L, Jie W. Effects of the nursing care of mutual participation model on the rehabilitation of inpatients with early schizophrenia. Chinese Journal of Clinical Rehabilitation 2004;8(24):4958-9.
97. Yang W, Liu X-Q, Li X-W. A ramdomized controlled clinical study of aripiprazole in the treatment of childhood schizophrenia Hunan Medical Journal 2007;24(6):942-4. [CHINESE: Academic Journals; MEDLINE: ]
98. Yao H. A study of risperidone in the treatment of child schizophrenia. Journal of Clinical Psychological Medicine 2003, issue 02.
99. Yi Q-M, Fan W-L, Chen Z-Q. The contrast investigation between quetiapine and perphenazlne in the treatment of first episode of schizophrenia in children Journal of the North Sichuan Medical College 2006;2(6):522-4. [CHINESE: Academic Journals; MEDLINE: ]
100. Zhang Y, Zhang H, Gu W. A control study of aripiprazole in the treatment of childhood schizophrenia Journal of Clinical Psychosomatic Diseases 2007;13(2):122-4. [CHINESE: Academic Journals; MEDLINE: ]
101. Zhou Z-H, Yuan G-Z, Zhu H-M. Effects of olanzapine treatment on the auditory evoked event-related potential P300 in childhood and adolescent schizophrenia Chinese Journal of Behavioral Medical Science 2007;16(10):906-7. [CHINESE: Academic Journals; MEDLINE: ]
102. [only Chinese Title available] Journal of Applied Clinical Pediatrics
103. Chinese Journal of Nervous and Mental Diseases 2002;28(5):365-7.
104. Alaghband-rad J, Shahrivar Z, Mahmoodi J, Salesian N. First episode psychoses among Iranian adolescents. Schizophrenia Research 2006;86(Suppl 1):S65.
105. Alaghband-rad J, Sharifi V, Amini H, Shahrivar Z, Mottaghipour Y, Mahmoodi J, et al.Management of first episode psychoses in Iran: unique features and challenges. Schizophrenia Research 2006;86(Suppl 1):S42.
106. AstraZeneca. A 6-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, phase 3b study of the efficacy and safety of quetiapine fumarate (Seroquel™) immediate-release tablets compared with placebo in adolescents with schizophrenia, 2004. http:www.clinicaltrials.gov.
107. AstraZeneca. A 26-week, multicenter, open-label phase 3b study of the safety and tolerability of quetiapine fumarate (Seroquel™) immediate-release tablets in daily doses of 400 mg to 800 mg in children and adolescents with bipolar I disorder and adolescents with schizophrenia, 2005. http:www.clinicaltrials.gov.
108. Bechdolf A. Development and pilot evaluation of modified cognitive behavioural therapy for adolescents with early onset psychosis, 2007. http:www.clinicaltrials.gov.
109. Pfizer. Six week, double-blind, placebo controlled phase III trial evaluating the efficacy, safety and pharmacokinetics of flexible doses of oral ziprasidone in adolescent subjects with schizophrenia, 2005. http:www.clinicaltrials.gov.
110. Almandil NB, Wong IC. Review on the current use of antipsychotic drugs in children and adolescents. Archives of Disease in Childhood. Education and Practice Edition 2011;96(5):192-6. [PUBMED: 21771730]
111. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313:1200. [: OLZ020600]
112. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City: The University of Iowa, 1983.
113. Andreasen NC. The Scale for the Assessment of Positive Symptoms, (SAPS). Iowa City: The University of Iowa, 1984.
114. Andreasen NC, Pressler M, Nopoulos P, Miller D, Ho BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biological Psychiatry 2010;67(3):255-62. [PUBMED: 19897178]
115. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). 4th Edition. Washington DC: APA, 1994.
116. Ardizzone I, Nardecchia F, Marconi A, Carratelli TI, Ferrara M. Antipsychotic medication in adolescents suffering from schizophrenia: a meta-analysis of randomized controlled trials. Psychopharmacology Bulletin 2010;43(2):45-66. [PUBMED: 21052042]
117. Ballageer T, Malla A, Manchanda R, Takhar J, Haricharan R. Is adolescent-onset first-episode psychosis different from adult onset?. Journal of the American Academy of Child and Adolescent Psychiatry 2005;44(8):782-9.
118. Barnes TR. A rating scale for drug-induced akathisia. British Journal of Psychiatry 1989;154:672-6.
119. Bland JM, Kerry SM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
120. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al.The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
121. Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, Fischer BA, et al.Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophrenia Bulletin 2010;36(1):71-93. [PUBMED: 19955390]
122. Bunney WEJ, Hamburg DA. Methods for reliable longitudinal observation of behavior. Archives of General Psychiatry 1963;9:280-294.
123. Caccia S, Clavenna A, Bonati M. Antipsychotic drug toxicology in children. Expert Opinion on Drug Metabolism & Toxicology 2011;7(5):591-608. [PUBMED: 21401439]
124. Clark A, Lewis S. Treatment of schizophrenia in childhood and adolescence. Journal of Child Psychology and Psychiatry 1998;39:1071-81.
125. Crossley NA, Constante M, McGuire P, Power P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. British Journal of Psychiatry 2010;196(6):434-9.
126. Datta SS, Kumar A, Wright S, Russell P. Typical antipsychotics for psychosis in adolescents. Cochrane Database of Systematic Reviews Protocol published in Jan 2012.
127. De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: a systematic review of randomized, placebo controlled trials and guidelines for clinical practice. European Psychiatry 2011;26(3):144-58. [PUBMED: 21295450]
128. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium, 25-28 October 2000, Cape Town, Africa.
129. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
130. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
131. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
132. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
133. Endicott J, Nee J, Yang R, Wohlberg C. Pediatric Quality of Life Enjoyment and Satisfaction Questionnaire (PQ-LES-Q): reliability and validity. Journal of the American Academy of Child and Adolescent Psychiatry 2006;45(4):401-7.
134. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
135. Gilat Y, Ben-Dor DH, Magen A, Wolovick L, Vekslerchik M, Weizman A, et al.Trends in prescribing of psychotropic medications for inpatient adolescents in Israel: a 10 years retrospective analysis. European Psychiatry 2011;26(4):265-9. [PUBMED: 21276716]
136. Gogtay N, Vyas NS, Testa R, Wood SJ, Pantelis C. Age of onset of schizophrenia: perspectives from structural neuroimaging studies. Schizophrenia Bulletin 2011;37(3):504-13.
137. Gulliford MC, Ukoumunne OC, Chinn S. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
138. Guy U. ECDEU Assessment Manual for Psychopharmacology. Revised. Rockville: National Institute of Mental Health, 1976.
139. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery, and Psychiatry 1960;23:56-62. [PUBMED: 14399272]
140. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
141. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
142. Hodges K. Child and Adolescent Functional Assessment Scale. Ypsilanti, Michigan: Eastern Michigan University, Department of Psychology, 1990.
143. Hollis CP. Adolescent schizophrenia. Advances in Psychiatric Treatment 2000;6:83-92.
144. Hollis CP. The adult outcomes of child and adolescent-onset schizophrenia: diagnostic stability and predictive validity. American Journal of Psychiatry 2000;157:1653-9.
145. Hutton JL. Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials. British Journal of Haematology 2009;146(1):27-30.
146. Imran S, Datta SS, Vincent E, Whitfield J, Clark A. Antipsychotic prescribing: old wine in new bottles?. Child and Adolescent Mental Health Nov 2011; Vol. 16, issue 4:218-221. [DOI: 10.1111/j.1475-3588.2011.00610.x]
147. Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. American Journal of Psychiatry 2001;158(3):360-9.
148. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
149. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bulletin 1987;13:261-76.
150. Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Schizophrenia Bulletin 2007;33(5):1082-3.
151. Kennedy E, Kumar A, Datta SS. Antipsychotic medication for childhood-onset schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. [DOI: 10.1002/14651858.CD004027.pub2; PUBMED: 17636744]
152. Kumra S, Oberstar JV, Sikich L, Findling RL, McClellan JM, Vinogradov S, et al.Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophrenia Bulletin 2008;34(1):60-71. [PUBMED: 17923452]
153. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
154. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of Brief Psychiatric Rating Scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
155. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
156. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. The New England Journal of Medicine 2005;353(12):1209-23. [PUBMED: 16172203]
157. Marshall M, Lockwood A, Bradley C, Adams CE, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
158. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports 1962;10:799-812.
159. Owen MJ, O'Donovan MC, Thapar A, Craddock N. Neurodevelopmental hypothesis of schizophrenia. British Journal of Psychiatry 2011;198(3):173-5.
160. Rapoport JL, Gogtay N. Childhood onset schizophrenia: support for a progressive neurodevelopmental disorder. International Journal of Developmental Neuroscience 2011;29(3):251-8.
161. Schaffer D, Gould MS, Brasic J. A Children's Global Assessment Scale (CGAS). Archives of General Psychiatry 1983;40:1228-31.
162. Schubart CD, Van Gastel WA, Breetvelt EJ, Beetz SL, Ophoff RA, Sommer IE, et al.Cannabis use at a young age is associated with psychotic experiences. Psychological Medicine 2010;Oct 7:1-10.
163. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al.Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
164. Seeman P. Atypical antipsychotics: mechanism of action. Canandian Journal of Psychiatry 2002;47(1):27-38.
165. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970;(Suppl 212):11-19.
166. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
167. Werry JS, McClellan JM, Chard L. Childhood and adolescent schizophrenic, bipolar, and schizoaffective disorders: a clinical and outcome study. Journal of the American Academy of Child and Adolescent Psychiatry 1991;30(3):457-65.
168. Werry JS. Child and adolescent (early onset) schizophrenia: a review in light of DSM-IIIR. Journal of Autism and Developmental Disorders 1992;22:601-24.
169. World Health Organization. ICD-10. The ICD-10 Classification of Mental and Behavioural Disorders. Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO, 1992.
170. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. Journal of Clinical Psychiatry 2003;64(6):663-7. [PUBMED: 12823080]
171. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al.Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
172. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. The British Journal of Psychiatry 1978;133:429-35. [PUBMED: 728692]
173. Yudofsky SC, Silver JM, Jackson W, Endicott J, Williams D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. The American Journal of Psychiatry 1986;143(1):35-9. [PUBMED: 3942284]
174. Zammit S, Lewis G, Dalman C, Allebeck P. Examining interactions between risk factors for psychosis. British Journal of Psychiatry 2010;197(3):207-11.